CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma

Liu, Tang, Shen, Jacson K., Li, Zhihong, Choy, Edwin, Hornicek, Francis J., Duan, Zhenfeng·2016·Cancer Letters
DOI 10.1016/j.canlet.2016.01.030PMC PMC4772675
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2016.01.030

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 11 references

Research works printed but not linked: 78

  1. Borden, 2003, Soft tissue sarcomas of adults: state of the translational science, Clin. Cancer Res, 9, 1941
  2. Harwood, 2015, Targeted chemotherapy in bone and soft-tissue sarcoma, Orthop. Clin. North Am, 46, 587, 10.1016/j.ocl.2015.06.011 · DOI
  3. de Alava, 2007, Molecular pathology in sarcomas, Clin. Transl. Oncol, 9, 130, 10.1007/s12094-007-0027-2 · DOI
  4. Riggi, 2007, Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET, J. Pathol, 213, 4, 10.1002/path.2209 · DOI
  5. Movva, 2015, Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets, Oncotarget, 12234, 10.18632/oncotarget.3498 · DOI
  6. Taylor, 2011, Advances in sarcoma genomics and new therapeutic targets, Nat. Rev. Cancer, 11, 541, 10.1038/nrc3087 · DOI
  7. Demicco, 2012, New therapeutic targets in soft tissue sarcoma, Adv. Anat. Pathol, 19, 170, 10.1097/PAP.0b013e318253462f · DOI
  8. Zhang, 2014, Epigenetic regulators: new therapeutic targets for soft tissue sarcoma, Cancer Cell Microenviron, 1, e191
  9. Lu, 2015, Modeling cancer processes with CRISPR-Cas9, Trends Biotechnol, 33, 317, 10.1016/j.tibtech.2015.03.007 · DOI
  10. Agrawal, 2003, RNA interference: biology, mechanism, and applications, Microbiol. Mol. Biol. Rev, 67, 657, 10.1128/MMBR.67.4.657-685.2003 · DOI
  11. Wilson, 2001, The LoxP/CRE system and genome modification, Methods Mol. Biol, 158, 83
  12. Maizels, 2013, Genome engineering with Cre-loxP, J. Immunol, 191, 5, 10.4049/jimmunol.1301241 · DOI
  13. Barrangou, 2014, RNA events. Cas9 targeting and the CRISPR revolution, Science, 344, 707, 10.1126/science.1252964 · DOI
  14. Cong, 2013, Multiplex genome engineering using CRISPR/Cas systems, Science, 339, 819, 10.1126/science.1231143 · DOI · Paper page
  15. Bortesi, 2015, The CRISPR/Cas9 system for plant genome editing and beyond, Biotechnol. Adv, 33, 41, 10.1016/j.biotechadv.2014.12.006 · DOI
  16. Rath, 2015, The CRISPR-Cas immune system: biology, mechanisms and applications, Biochimie, 117, 119, 10.1016/j.biochi.2015.03.025 · DOI · Paper page
  17. Sanchez-Rivera, 2015, Applications of the CRISPR-Cas9 system in cancer biology, Nat. Rev. Cancer, 15, 387, 10.1038/nrc3950 · DOI · Paper page
  18. Wen, 2016, CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies, Int. J. Cancer, 138, 1328, 10.1002/ijc.29626 · DOI
  19. Xiao-Jie, 2015, CRISPR-Cas9: a new and promising player in gene therapy, J. Med. Genet, 52, 289, 10.1136/jmedgenet-2014-102968 · DOI · Paper page
  20. Zhang, 2014, CRISPR/Cas9 for genome editing: progress, implications and challenges, Hum. Mol. Genet, 23, R40, 10.1093/hmg/ddu125 · DOI
  21. Niu, 2014, Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos, Cell, 156, 836, 10.1016/j.cell.2014.01.027 · DOI · Paper page
  22. Sanchez-Rivera, 2014, Rapid modelling of cooperating genetic events in cancer through somatic genome editing, Nature, 516, 428, 10.1038/nature13906 · DOI
  23. Feldser, 2010, Stage-specific sensitivity to p53 restoration during lung cancer progression, Nature, 468, 572, 10.1038/nature09535 · DOI
  24. Gupta, 2014, Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9, J. Clin. Invest, 124, 4154, 10.1172/JCI72992 · DOI
  25. Matano, 2015, Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids, Nat. Med, 21, 256, 10.1038/nm.3802 · DOI · Paper page
  26. Wesche-Soldato, 2008, Hydrodynamic delivery of siRNA in a mouse model of sepsis, Methods Mol. Biol, 442, 67, 10.1007/978-1-59745-191-8_5 · DOI
  27. Xue, 2014, CRISPR-mediated direct mutation of cancer genes in the mouse liver, Nature, 514, 380, 10.1038/nature13589 · DOI · Paper page
  28. Platt, 2014, CRISPR-Cas9 knockin mice for genome editing and cancer modeling, Cell, 159, 440, 10.1016/j.cell.2014.09.014 · DOI · Paper page
  29. Albers, 2015, A versatile modular vector system for rapid combinatorial mammalian genetics, J. Clin. Invest, 125, 1603, 10.1172/JCI79743 · DOI
  30. Blasco, 2014, Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology, Cell Rep, 9, 1219, 10.1016/j.celrep.2014.10.051 · DOI
  31. Choi, 2014, Targeted genomic rearrangements using CRISPR/Cas technology, Nat. Commun, 5, 3728, 10.1038/ncomms4728 · DOI
  32. Tschoep, 2007, Gene expression profiling in sarcomas, Crit. Rev. Oncol. Hematol, 63, 111, 10.1016/j.critrevonc.2007.04.001 · DOI
  33. Lagutina, 2015, Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease, PLoS Genet, 11, e1004951, 10.1371/journal.pgen.1004951 · DOI
  34. Torres, 2014, Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system, Nat. Commun, 5, 3964, 10.1038/ncomms4964 · DOI
  35. Aubrey, 2015, An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo, Cell Rep, 10, 1422, 10.1016/j.celrep.2015.02.002 · DOI
  36. Chen, 2015, Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis, Cell, 160, 1246, 10.1016/j.cell.2015.02.038 · DOI · Paper page
  37. Post, 2012, Mouse models of sarcomas: critical tools in our understanding of the pathobiology, Clin. Sarcoma Res, 2, 20, 10.1186/2045-3329-2-20 · DOI
  38. Suva, 2007, Sarcomas: genetics, signalling, and cellular origins. Part 2: TET-independent fusion proteins and receptor tyrosine kinase mutations, J. Pathol, 213, 117, 10.1002/path.2208 · DOI
  39. Lang, 2004, Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006 · DOI · Paper page
  40. Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
  41. Lin, 2009, Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice, Carcinogenesis, 30, 1789, 10.1093/carcin/bgp180 · DOI
  42. Rauch, 2010, The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice, PLoS ONE, 5, 10.1371/journal.pone.0015755 · DOI
  43. Ng, 2012, Genetically engineered mouse models and human osteosarcoma, Clin. Sarcoma Res, 2, 19, 10.1186/2045-3329-2-19 · DOI
  44. Lagutina, 2002, Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors, Mol. Cell. Biol, 22, 7204, 10.1128/MCB.22.20.7204-7216.2002 · DOI
  45. Keller, 2004, Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin, Genes Dev, 18, 2608, 10.1101/gad.1243904 · DOI
  46. Keller, 2004, Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function, Genes Dev, 18, 2614, 10.1101/gad.1244004 · DOI
  47. Rubin, 2011, Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma, Cancer Cell, 19, 177, 10.1016/j.ccr.2010.12.023 · DOI
  48. Tsumura, 2006, Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice, Oncogene, 25, 7673, 10.1038/sj.onc.1209749 · DOI
  49. Doyle, 2010, p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma, J. Pathol, 222, 129, 10.1002/path.2748 · DOI
  50. Haldar, 2007, A conditional mouse model of synovial sarcoma: insights into a myogenic origin, Cancer Cell, 11, 375, 10.1016/j.ccr.2007.01.016 · DOI
  51. Charytonowicz, 2012, PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma, J. Clin. Invest, 122, 886, 10.1172/JCI60015 · DOI
  52. Joseph, 2008, The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells, Cancer Cell, 13, 129, 10.1016/j.ccr.2008.01.003 · DOI
  53. Hayashi, 2011, Molecular approach to uterine leiomyosarcoma: LMP2-deficient mice as an animal model of spontaneous uterine leiomyosarcoma, Sarcoma, 2011, 476498, 10.1155/2011/476498 · DOI
  54. Strizzi, 2007, Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice, J. Pathol, 211, 36, 10.1002/path.2083 · DOI
  55. Xing, 2009, A role for BRCA1 in uterine leiomyosarcoma, Cancer Res, 69, 8231, 10.1158/0008-5472.CAN-09-2543 · DOI
  56. Mou, 2015, Precision cancer mouse models through genome editing with CRISPR-Cas9, Genome Med, 7, 53, 10.1186/s13073-015-0178-7 · DOI
  57. Malina, 2013, Repurposing CRISPR/Cas9 for in situ functional assays, Genes Dev, 27, 2602, 10.1101/gad.227132.113 · DOI
  58. Feng, 2015, Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system, J. Orthop. Res, 33, 199, 10.1002/jor.22745 · DOI
  59. Duan, 2012, Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation, Clin. Cancer Res, 18, 4580, 10.1158/1078-0432.CCR-12-1157 · DOI
  60. Zhou, 2015, Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth, Sci. Rep, 5, 10433, 10.1038/srep10433 · DOI
  61. Takahashi, 2015, Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer, Mol. Cancer Ther, 14, 1705, 10.1158/1535-7163.MCT-14-0142 · DOI
  62. Jia, 2014, Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells, Cancer Lett, 342, 104, 10.1016/j.canlet.2013.08.040 · DOI
  63. Susa, 2010, Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma, PLoS ONE, 5, 10.1371/journal.pone.0010764 · DOI
  64. Kasap, 2014, DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets, Nat. Chem. Biol, 10, 626, 10.1038/nchembio.1551 · DOI
  65. Neggers, 2015, Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing, Chem. Biol, 22, 107, 10.1016/j.chembiol.2014.11.015 · DOI
  66. Yao, 2009, The expression of CRM1 is associated with prognosis in human osteosarcoma, Oncol. Rep, 21, 229
  67. Kazim, 2015, Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer, Mol. Cancer Ther, 14, 1570, 10.1158/1535-7163.MCT-15-0104 · DOI
  68. De Cesare, 2015, Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin, Oncotarget, 6, 13119, 10.18632/oncotarget.3761 · DOI
  69. Rath, 2012, Kinesins and cancer, Nat. Rev. Cancer, 12, 527, 10.1038/nrc3310 · DOI
  70. Houghton, 2007, The pediatric preclinical testing program: description of models and early testing results, Pediatr. Blood Cancer, 49, 928, 10.1002/pbc.21078 · DOI · Paper page
  71. Souid, 2010, A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study, Pediatr. Blood Cancer, 55, 1323, 10.1002/pbc.22609 · DOI
  72. O'Malley, 2015, Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma, Ann. Diagn. Pathol, 19, 113, 10.1016/j.anndiagpath.2015.02.008 · DOI
  73. Chen, 2013, Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study, N. Am. J. Med. Sci, 5, 386, 10.4103/1947-2714.114172 · DOI
  74. Idbaih, 2014, Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib, Neurology, 83, 1478, 10.1212/WNL.0000000000000880 · DOI
  75. Kopetz, 2015, Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer, J. Clin. Oncol, 33, 4032, 10.1200/JCO.2015.63.2497 · DOI · Paper page
  76. Shalem, 2014, Genome-scale CRISPR-Cas9 knockout screening in human cells, Science, 343, 84, 10.1126/science.1247005 · DOI · Paper page
  77. Cho, 2014, Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases, Genome Res, 24, 132, 10.1101/gr.162339.113 · DOI · Paper page
  78. Zhang, 2015, CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs, Sci. Rep, 5, 16277, 10.1038/srep16277 · DOI

Cited by

Sorted by citations

See all 30

Metadata

Authors
Liu, T., Shen, J. K., Li, Z., Choy, E., Hornicek, F. J., & Duan, Z.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2016-04
Volume
373
Issue
1
Pages
109-118
ISSN
0304-3835
DOI
10.1016/j.canlet.2016.01.030
PMC
PMC4772675
Cited by
30
References
11
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Gattegno and Wechsler funds
  • Kenneth Stanton Fund
  • Jennifer Hunter Yates Foundation
  • Sarcoma Foundation of America
  • National Cancer Institute (UO1, CA 151452-01)
  • Sarcoma SPORE (5U54 CA168512-02)
  • Academic Enrichment Fund of MGH Orthopaedics
  • China Scholarship Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review